Skip to main content

Table 2 Between groups analysis

From: Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial

 PlaceboNutraceuticalInference
Mean (SD)nMean (SD)nDifference/OR (95% CI)p
Encrustation
 Kidney stent end64.73 (241.74)497.66 (23.69)5057.07 (−11.1, 125.25)0.89
 Bladder stent end105.51 (304.99)4930.16 (142.52)5075.35 (−19.3, 170.00)0.65
 Sum of stent ends170.24 (513.58)4937.82 (159.24)5075.35 (−19.28, 169.99)0.65
 Maximum of stent ends105.69 (304.93)4930.34 (142.49)50132.43 (−18.62, 283.47)0.67
Encrustation adjusted for baseline urine pH
 Sum of stent ends78.34 (158.44)3911.11 (32.97)3767.23 (19.18, 115.29)0.006
Encrustation adjusted for baseline urine pH, age, gender and indwelling duration
 Sum of stent ends57.57 (122.09)3918.27 (48.42)3739.0 (2.02, 76.57)0.039
Urine pH
 pH reduction baseline (24 h) to day 210.39 (0.7)280.86 (0.78)32−0.47 (−0.85, −0.084)0.018
 pH reduction days 1–3 to day 210.17 (0.49)360.54 (0.58)36−0.37 (−0.62, −0.11)0.005
 pH slope−.0061 (.013)40−.014 (0.02)390.008 (0.00006, 0.016)0.042
Stent removal
 Removal surgery time (min)13.8 (30.5)527.23 (13.5)52 0.76
 Removal surgery time (adjusted, min)40.9 (5.8)529.5 (4.15)52 < 0.001
 N%n%Odds ratio 
Stent removed at first attempt4748.55051.52.66 [0.49–14.37]0.44